iBio, Inc. (IBIO)
IBIO moved a median of -0.38% 30 minutes after news, and -0.76% by the close. How IBIO actually reacts to news — the realized, point-in-time move the market made, measured across 263 labeled events over the last three years with zero look-ahead.
IBIO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.42% | 32% | 260 |
| 30-min | -0.38% | 43% | 263 |
| 60-min | -0.46% | 40% | 263 |
| to close | -0.76% | 41% | 255 |
| Middle 50% of IBIO reactions | -2.96% to +1.88% |
|---|---|
| Median reaction (30-min) | -0.38% |
| Measured reactions | 263 |
Half of all iBio, Inc. news events land between -2.96% and +1.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IBIO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 31 | +0.27% | 52% | +0.46% |
| Rating reiterations | 17 | -1.95% | 24% | -4.54% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how IBIO ranks against every other measured name →
That’s how IBIO usually reacts — get an email when it moves on news →Email me when IBIO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IBIO's baseline. Nothing else.
Recent IBIO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K iBio, Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | -12.91% | |
| iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy | Press release | GlobeNewswire | -0.10% | -12.91% | |
| Form 8-K iBio, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | -0.83% | |
| Form ARS iBio, Inc. For: Jun 30 | SEC filing · Form ARS | SEC EDGAR | -1.91% | -0.76% | |
| Form DEF 14A iBio, Inc. For: Sep 04 | SEC filing · Form DEF | SEC EDGAR | -1.91% | -0.76% | |
| iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference | Press release | GlobeNewswire | +2.38% | +3.97% | |
| Form 10-K iBio, Inc. For: Jun 30 | SEC filing · Form 10-K | SEC EDGAR | -2.82% | -4.22% | |
| Form 8-K iBio, Inc. For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | -2.82% | -4.22% | |
| iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.82% | -4.22% | |
| Form PRE 14A iBio, Inc. For: Oct 14 | SEC filing · Form PRE | SEC EDGAR | +0.63% | +0.00% | |
| Form 8-K iBio, Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +1.39% | |
| iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer | Press release | GlobeNewswire | +0.69% | +1.39% | |
| Form 8-K iBio, Inc. For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | +1.44% | -1.44% | |
| Form 8-K iBio, Inc. For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +1.14% | -0.57% | |
| iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Press release | GlobeNewswire | +1.14% | -0.57% | |
| iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | Press release | GlobeNewswire | +0.53% | -6.88% | |
| iBio to Participate in Upcoming Healthcare Investor Conferences | Press release | GlobeNewswire | -3.07% | +2.79% | |
| Form 10-Q iBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.47% | -4.32% | |
| Form 8-K iBio, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -2.47% | -4.32% | |
| iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -2.47% | -4.32% | |
| Form 8-K iBio, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.16% | -4.05% | |
| iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | Press release | GlobeNewswire | -0.30% | +4.27% | |
| Form 8-K/A iBio, Inc. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.43% | |
| Form 8-K iBio, Inc. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -2.20% | -1.32% | |
| iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | Press release | GlobeNewswire | -2.20% | -1.32% | |
| iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) | Press release | GlobeNewswire | +0.83% | +2.08% | |
| Form 8-K iBio, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | -2.76% | -1.57% | |
| Form EFFECT iBio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -2.76% | -1.57% | |
| iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss | Press release | GlobeNewswire | -2.76% | -1.57% | |
| Form 8-K iBio, Inc. For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -3.32% | +5.08% | |
| Form S-3 iBio, Inc. | SEC filing · Form S-3 | SEC EDGAR | -3.32% | +5.08% | |
| iBio to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.24% | +1.65% | |
| Form 10-Q iBio, Inc. For: Dec 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.93% | -4.74% | |
| Form 8-K iBio, Inc. For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -4.93% | -4.74% | |
| Form EFFECT iBio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.41% | -6.20% | |
| iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -4.93% | -4.74% | |
| Form S-3 iBio, Inc. | SEC filing · Form S-3 | SEC EDGAR | +3.40% | +11.65% | |
| Form D iBio, Inc. | SEC filing · Form D | SEC EDGAR | -1.26% | -5.46% | |
| Form 8-K iBio, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -0.15% | -5.93% | |
| iBio Announces $26 Million Private Placement | Press release | GlobeNewswire | -0.96% | +3.85% | |
| iBio to Participate in the 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +2.67% | +4.46% | |
| Form 8-K iBio, Inc. For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +5.00% | |
| Form 10-Q/A iBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.43% | -5.17% | |
| Form 8-K iBio, Inc. For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +8.04% | |
| Form 10-Q iBio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.22% | — | |
| Form 8-K iBio, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -3.22% | — | |
| iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -3.22% | — | |
| Form 8-K iBio, Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -4.00% | |
| Form 8-K iBio, Inc. For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +1.18% | -8.28% | |
| iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance | Press release | GlobeNewswire | +1.18% | -8.28% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IBIO section they belong to.
Where else IBIO is measured.
IBIO earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | 265 | -0.01% | 44% |
| HUTCHMED (China) Limited - American Depositary Shares (HCM) | 263 | 0.00% | 47% |
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
| Haemonetics Corporation (HAE) | 261 | -0.07% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is iBio, Inc.'s median reaction calculated?
Every labeled IBIO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 263 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of IBIO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IBIO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.